Can guanfacine cause decreased libido?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Guanfacine Decrease Libido?

Yes, guanfacine can cause decreased libido, though this adverse effect occurs infrequently based on FDA drug labeling data.

Evidence from FDA Drug Label

The FDA label for guanfacine explicitly lists "libido decrease" as a documented adverse reaction 1. In controlled clinical trials, this side effect was reported in 3% or less of patients receiving guanfacine with a diuretic 1. The FDA categorizes decreased libido under CNS (central nervous system) adverse reactions, alongside amnesia, confusion, depression, and insomnia 1.

Additionally, impotence (erectile dysfunction) was reported in clinical trials, with incidence ranging from 0-7% depending on dose, showing a clear dose-response relationship at higher doses (3 mg showed 3-4% incidence) 1. This sexual dysfunction profile is consistent with other alpha-2 adrenergic agonists.

Clinical Context and Mechanism

Guanfacine is an alpha-2A adrenergic receptor agonist used primarily for ADHD treatment 2. The most common adverse effects are:

  • Somnolence (38.6% in recent meta-analysis)
  • Dry mouth (up to 54% at higher doses)
  • Fatigue (15.2%)
  • Headache (20.5%)
  • Dizziness and constipation 3, 2

Sexual side effects (decreased libido and impotence) are significantly less common than these primary adverse effects but are nonetheless documented and clinically relevant 1.

Dose-Response Relationship

The FDA data shows that sexual dysfunction, including both decreased libido and impotence, demonstrates a dose-dependent pattern. At lower doses (0.5-1 mg), impotence was essentially absent (0%), but increased to 7% at 2 mg and 3-4% at 3 mg doses 1. This suggests that if decreased libido occurs, dose reduction may be a viable management strategy.

Clinical Recommendations

When prescribing guanfacine, specifically counsel patients about the possibility of decreased libido and sexual dysfunction, though emphasize this occurs in a minority of patients (≤3%). Monitor for this side effect during follow-up visits, particularly at higher doses (≥2 mg/day). If decreased libido develops and is clinically significant:

  • Consider dose reduction as the first intervention
  • Evaluate for other contributing factors (depression, fatigue, other medications)
  • If symptoms persist and are intolerable, consider switching to alternative ADHD medications

Important Caveats

The sexual side effects of guanfacine are substantially less frequent than the primary adverse effects of somnolence, dry mouth, and fatigue 2. However, sexual dysfunction can significantly impact quality of life and medication adherence, making it an important consideration in shared decision-making with patients 4.

Interestingly, a recent systematic review found that 40 drugs showed signals for decreased libido in FAERS data mining, with many not listing this risk in their prescribing information 4. Guanfacine's inclusion of this adverse effect in FDA labeling represents appropriate transparency about this risk.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.